Diagnostic prediction models for CT Confirmed and bacterial rhinosinusitis in primary care: individual participant data meta-analysis

INTRODUCTION
Acute rhinosinusitis (ARS), an inflammation of the nasal cavity and paranasal sinuses lasting <12 weeks, is a common reason for primary care visits. Despite evidence that a bacterium can be identified in only a minority of patients with suspected ARS, antibiotics are frequently prescribed for such patients. This potentially leads to unnecessary side effects, medical costs, and the emergence of antimicrobial resistance.

To help physicians identify adults with suspected ARS who are most likely to benefit from antibiotics, prediction models were derived using logistic regression modelling. However, such models have been derived from only one study that does not provide the opportunity to assess the models’ generalisability, and the sample sizes of the individual studies in this field do not meet the required minimum sample size to develop robust models. In this study, therefore, an individual participant data meta-analysis (IPD-MA) was performed of multiple studies to develop prediction models for diagnosing CT Confirmed ARS and culture Confirmed ARS in adults presenting to primary care with symptoms of suspected ARS.

METHOD
The protocol of this IPD-MA has been registered in PROSPERO (CRD42020175659) and has been published elsewhere. The study was reported according to the PRISMA statement for diagnostic test accuracy studies and the PRISMA-IPD statement.

Study identification and selection
A systematic search was conducted to identify eligible studies. First, two authors

T Takada, MD, PhD, visiting researcher, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands; associate professor, Department of General Medicine, Shirakawa Satellite for Teaching And Research (STAR), Fukushima Medical University, Fukushima, Japan; J Hoogland, MD, PhD, candidate; JB Reitsma, MD, PhD, associate professor; RP Venekamp, MD, PhD, associate professor; R P Venekamp, MD, PhD; professor; R P Venekamp, MD, PhD, associate professor; R P Venekamp, MD, PhD; associate professor; R P Venekamp, MD, PhD; specialist in general medicine, Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; M Lindbaek, MD, PhD, professor, Department of General Practice, Institute of Health and Society, University Hospital of Oslo, Oslo, Norway; T Auto, MD, PhD, head and neck surgeon; Head & Neck Surgery, Oulu University Hospital, Oulu, Finland; O-P Alho, MD, PhD, professor of Otorhinolaryngology, PEDEGO Research Unit, University of Oulu, Finland; professor of otorhinolaryngology, Department of Otorhinolaryngology, Head & Neck Surgery, Oulu University Hospital, Oulu, Finland; MH Ebell, MD, MS, professor, Department of Epidemiology and Biostatistics, College of Public Health, University of Georgia, Athens, GA, US.

Address for correspondence
Roderick P Venekamp, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Str. 6131, PO Box 85500, 3508 GA Utrecht, the Netherlands.

Email: R.P.Venekamp@umcutrecht.nl

Submitted: 9 October 2021; Editor’s response: 9 December 2021; final acceptance: 1 February 2022.

©The Authors
This is the full-length article published online 12 Jul 2022 of an abridged version published in print. Cite this version as: Br J Gen Pract 2022; DOI: https://doi.org/10.3399/BJGP.2021.0585
Acute rhinosinusitis (ARS) is a very common condition in which it is notoriously challenging to identify patients who could potentially benefit from antibiotic treatment. Existing prediction models for computed tomography (CT)-confirmed ARS and culture-confirmed acute bacterial rhinosinusitis (ABRS) — that is, conditions associated with antibiotic benefit — are based on a single, relatively small dataset that does not provide the opportunity to assess the model performance in other datasets with new patients. In the current individual participant data meta-analyses, prediction models for those two outcomes were developed based on readily available variables [previous diagnosis of ARS, preceding upper respiratory tract infection, anosmia, double sickening, purulent nasal discharge on examination, need for antibiotics as judged by physician, and C-reactive protein (CRP) for CT-confirmed ARS; and pain in teeth, purulent nasal discharge on examination, and CRP for culture-confirmed ABRS]. These simple models could be useful to rule out the target condition with fair discrimination and calibration, and hence safely reduce the overall use of antibiotics among adults with symptoms of suspected ARS in high-prescribing countries.

How this fits in

Acute rhinosinusitis (ARS) is a very common condition in which it is notoriously challenging to identify patients who could potentially benefit from antibiotic treatment. Existing prediction models for computed tomography (CT)-confirmed ARS and culture-confirmed acute bacterial rhinosinusitis (ABRS) — that is, conditions associated with antibiotic benefit — are based on a single, relatively small dataset that does not provide the opportunity to assess the model performance in other datasets with new patients. In the current individual participant data meta-analyses, prediction models for those two outcomes were developed based on readily available variables [previous diagnosis of ARS, preceding upper respiratory tract infection, anosmia, double sickening, purulent nasal discharge on examination, need for antibiotics as judged by physician, and C-reactive protein (CRP) for CT-confirmed ARS; and pain in teeth, purulent nasal discharge on examination, and CRP for culture-confirmed ABRS]. These simple models could be useful to rule out the target condition with fair discrimination and calibration, and hence safely reduce the overall use of antibiotics among adults with symptoms of suspected ARS in high-prescribing countries.

How this fits in

Acute rhinosinusitis (ARS) is a very common condition in which it is notoriously challenging to identify patients who could potentially benefit from antibiotic treatment. Existing prediction models for computed tomography (CT)-confirmed ARS and culture-confirmed acute bacterial rhinosinusitis (ABRS) — that is, conditions associated with antibiotic benefit — are based on a single, relatively small dataset that does not provide the opportunity to assess the model performance in other datasets with new patients. In the current individual participant data meta-analyses, prediction models for those two outcomes were developed based on readily available variables [previous diagnosis of ARS, preceding upper respiratory tract infection, anosmia, double sickening, purulent nasal discharge on examination, need for antibiotics as judged by physician, and C-reactive protein (CRP) for CT-confirmed ARS; and pain in teeth, purulent nasal discharge on examination, and CRP for culture-confirmed ABRS]. These simple models could be useful to rule out the target condition with fair discrimination and calibration, and hence safely reduce the overall use of antibiotics among adults with symptoms of suspected ARS in high-prescribing countries.

How this fits in

Acute rhinosinusitis (ARS) is a very common condition in which it is notoriously challenging to identify patients who could potentially benefit from antibiotic treatment. Existing prediction models for computed tomography (CT)-confirmed ARS and culture-confirmed acute bacterial rhinosinusitis (ABRS) — that is, conditions associated with antibiotic benefit — are based on a single, relatively small dataset that does not provide the opportunity to assess the model performance in other datasets with new patients. In the current individual participant data meta-analyses, prediction models for those two outcomes were developed based on readily available variables [previous diagnosis of ARS, preceding upper respiratory tract infection, anosmia, double sickening, purulent nasal discharge on examination, need for antibiotics as judged by physician, and C-reactive protein (CRP) for CT-confirmed ARS; and pain in teeth, purulent nasal discharge on examination, and CRP for culture-confirmed ABRS]. These simple models could be useful to rule out the target condition with fair discrimination and calibration, and hence safely reduce the overall use of antibiotics among adults with symptoms of suspected ARS in high-prescribing countries.

Box 1. Definition of candidate predictors

| Predictor | Definition |
|-----------|------------|
| Previous diagnosis of ARS | History of previous ARS episode as reported by patients or based on medical record |
| Preceding URTI | History of URTI preceding the current episode of suspected ARS as reported by patients or based on medical records |
| Maxillary pain | Pain (any, unilateral, or bilateral) in maxillary sinus region as reported by patients |
| Pain in teeth | Pain in teeth as reported by patients |
| Anosmia | Loss of smell as reported by patients |
| Cacosmia | Sensation of bad smell as reported by patients |
| Double sickening | Worsening of symptoms after initial improvement of symptoms (‘two phases in the illness history’) as reported by patients or clinicians |
| Purulent nasal discharge on examination | The presence of purulent nasal discharge on rhinoscopy anterior or endoscopy |
| CRP | CRP levels (µL/mL) from blood samples collected by venepuncture (laboratory analysis) or fingerprick (using validated point-of-care testing devices) |
| Fever (>38°C) | Presence of fever (body temperature above 38°C) as reported by patients or measured by clinician |
| Severe pain | Pain score >8/10 or equivalent scores using other pain rating scales as reported by patients |

ARS = acute rhinosinusitis. CRP = C-reactive protein. URTI = upper respiratory tract infection.
Target conditions
The target conditions of interest were: 1) CT-confirmed ARS defined by a fluid level or total opacification in any maxillary sinus on CT scan; and 2) culture-confirmed ABRS defined by positive growth of bacterial pathogens in fluid from antral puncture.

Statistical analyses
Details of the statistical analyses are presented in Supplementary Box S1.

Handling of missing data. Missing values were imputed using multilevel chained equations. Results of analyses in each of 50 imputed datasets were pooled using Rubin’s rules.22

Sample size considerations. The maximum number of candidate predictors were calculated based on recent guidance.17 For CT-confirmed ARS (n = 426, outcome prevalence: 32.9%, n = 140), nine predictors could be included in the ordinary logistic regression analysis and 12 in penalised models. For culture-confirmed ABRS (n = 225, outcome prevalence: 30.2%, n = 68), the maximum number of predictors for the ordinary logistic regression analysis and penalised models were six and eight, respectively.

Model development. First, the relationship between CRP and each outcome were assessed (see Supplementary Figure S1) and a decision taken to use log-transformation. Second, heterogeneity in the relationship between individual predictors and each outcome was assessed, by fitting logistic regression models within each study. Next, heterogeneity in model performance across studies was further evaluated by internal–external cross-validation.23 Finally, a single logistic regression model for each outcome was fitted on all available data. To reduce model complexity and prevent overfitting, penalised logistic regression modelling was applied.24 To assess model performance, optimism-corrected area under the curve (AUC) and calibration slope were evaluated by internal validation using bootstrap resampling.25 AUC indicates the ability of a prediction model to differentiate between patients with and without an outcome, ranging between 0.5 (no discrimination) and 1.0 (excellent discrimination). The calibration slope is a measure of agreement between the observed and predicted risk of an outcome. Values <1 indicate that the prediction model is overfitted to the development data.

Clinical utility of the derived models. The potential consequences of using the models to select patients for withholding or considering antibiotic treatment based on the estimated risk of the target conditions are shown. In the absence of guidance about the appropriate risk threshold for clinical decision making, information about the consequences of applying various thresholds, that is, ranging from 0.1 to 0.9, are provided.

All analyses were performed using SPSS version 25 (SPSS Inc., Chicago, IL, US) and R version 3.6.3 (R Foundation for Statistical Computing, Vienna, Austria).

RESULTS
Study inclusion and study characteristics
Five eligible studies10,12–15 were identified from the recent review’s reference list.4 No further eligible studies were found from the electronic database searches or additional routes (Figure 1). Two studies14,15 (see Supplementary Table S2) were excluded as the authors were not able to provide IPD, leaving three studies with 426 participants for inclusion.10,12,13

The characteristics of included studies are shown in Supplementary Table S3. All three studies were conducted in primary care settings, although Autio et al included only military recruits.12 The other two studies included adults suspected of having ARS; however, Lindbaek et al had an additional criterion that antibiotics were considered necessary by the GP.10 All three studies were included in the IPD-MA for CT-confirmed ARS10,12,13 and two with 225 participants for culture-confirmed ABRS.12,13 Patient characteristics are summarised in Table 1. The overall prevalence was 32.9% (n = 140, range: 20.6%13 to 41.8%10) for CT-confirmed ARS and 30.2% ( n = 68, range: 16.0% 12 to 34.3%13) for culture-confirmed ABRS. The percentage of missing values for each variable is presented in Supplementary Table S4.

Quality assessment of included studies
The quality assessment of included studies is summarised in Supplementary Figure S2. Except for ‘flow and timing’, all items were rated as low risk of bias. In two studies,10,12 the risk of bias for ‘flow and timing’ was rated as unclear as around 15% of participants were excluded from the analyses because of missing information.

Model development
CT-confirmed ARS. When the model was fitted within each study, heterogeneity in the relationship between individual predictors was found and each outcome was not
It was therefore decided to pool the three datasets. Internal–external cross-validation showed substantial heterogeneity, especially in calibration performance between Hansen et al.13 and Lindbaek et al.10 (see Supplementary Figure S4). The most important difference between these studies was that all patients in Lindbaek et al.10 were judged to need antibiotics, whereas this judgement was not applied in Hansen et al.13 Therefore, the clinical judgement ‘this patient is likely to need antibiotic treatment’ (‘yes’ versus ‘unknown’) as a predictor was added in the current study.

Among the derived models, the penalised model consisting of seven variables showed the best performance with an optimism-corrected AUC of 0.73 (95% confidence interval [CI] = 0.69 to 0.78) and a calibration slope of 0.99 (95% CI = 0.72 to 1.19) (Table 2). The seven variables were:

- previous diagnosis of ARS;
- preceding URTI;
- anosmia;
- double sickening;
- purulent nasal discharge on examination;
- need for antibiotics as judged by physician; and
- log-transformed CRP.

Fever and severe pain did not have any added value. A web calculator of the penalised model is available online (https://pred-model.shinyapps.io/App_ARS_CT).
Table 1. Patient characteristics in each study

| Age, years, median (IQR) | Auto et al \(^\text{13}\) (n = 50) | Hansen et al \(^\text{13}\) (n = 175) | Lindbaek et al \(^\text{10}\) (n = 201) | Overall (n = 426) |
|--------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------|
| Sex, male, n (%)         | 48 (96.0)                   | 52 (29.7)                   | 64 (31.8)                   | 164 (38.5)      |
| Previous diagnosis of ARS, n (%) | 16 (32.0)       | 72 (40.9)                   | 119 (59.2)                  | 259 (60.8)      |
| Preceding URTI, n (%)    | 39 (78.0)                   | 148 (84.6)                  | 193 (96.0)                  | 380 (89.2)      |
| Maxillary pain, n (%)    | 37 (74.0)                   | 168 (96.0)                  | 136 (67.7)                  | 341 (80.0)      |
| Pain in teeth, n (%)     | 11 (22.0)                   | 105 (60.0)                  | 98 (48.8)                   | 214 (50.2)      |
| Anosmia, n (%)           | 13 (26.0)                   | 107 (61.1)                  | 143 (71.1)                  | 263 (61.7)      |
| Cacosmia, n (%)          | 15 (30.0)                   | 66 (37.7)                   | 54 (26.9)                   | 135 (31.7)      |
| Double sickening, n (%)  | 45 (90.0)                   | 119 (68.0)                  | 118 (58.7)                  | 282 (66.2)      |
| Pain scale, median (IQR) | 0.0 (0.0–3.0)               | 5.0 (2.0–7.3)               | 6.2 (3.5–7.8)               | 5.0 (2.0–7.3)   |
| Purulent nasal discharge on examination, n (%) | 27 (54.0)   | 47 (26.9)                   | 84 (41.8)                   | 158 (37.1)      |
| Fever (≥38°C), n (%)     | 0 (0.0)                     | 19 (10.9)                   | 16 (8.0)                    | 35 (8.2)        |
| CRP (µg/mL, median (IQR) | 3.1 (1.2–11.6)             | 18.0 (10.0–38.0)            | 9.0 (9.0–13.0)              | 10.0 (9.0–21.0) |
| CT-confirmed ARS, n (%)  | 20 (40.0)                   | 36 (20.6)                   | 84 (41.8)                   | 140 (32.9)      |
| Culture-confirmed ABRS, n (%) | 8 (16.0)                  | 60 (34.3)                   | NA                         | 68 (30.2)\(^*\) |

\(^*\)The proportion is the prevalence in the data combining the studies by Hansen et al and Auto et al. ABRS = acute bacterial rhinosinusitis. ARS = acute rhinosinusitis. CRP = C-reactive protein. CT = computed tomography. IQR = interquartile range. NA = not available. URTI = upper respiratory tract infection.

Table 2. Regression coefficients of the CT-confirmed ARS prediction model\(^2\)

| Coefficient Standard error | P-value | Regression coefficient |
|---------------------------|---------|------------------------|
| Intercept                 | -4.05   | 0.77                   | <0.01                  | -3.52       |
| Auto\(^1\)                | 1.37    | 0.51                   | 0.01                   | 1.08        |
| Lindbaek\(^1\)            | 1.13    | 0.31                   | 0.00                   | 0.99        |
| Previous diagnosis of ARS | -0.15   | 0.24                   | 0.52                   | -0.14       |
| Preceding URTI            | 0.56    | 0.48                   | 0.24                   | 0.41        |
| Maxillary pain            | 0.06    | 0.33                   | 0.85                   | 0.00        |
| Pain in teeth             | -0.13   | 0.26                   | 0.62                   | 0.00        |
| Anosmia                   | 0.39    | 0.27                   | 0.14                   | 0.30        |
| Cacosmia                  | -0.12   | 0.28                   | 0.68                   | 0.00        |
| Double sickening          | 0.73    | 0.35                   | 0.04                   | 0.67        |
| Purulent nasal discharge on examination | 1.00   | 0.23                   | <0.01                  | 0.97        |
| Log-transformed CRP       | 0.40    | 0.14                   | 0.01                   | 0.32        |

\(^1\)The ordinary logistic regression model showed an optimism-corrected AUC of 0.72 (95% CI = 0.68 to 0.77) and a calibration slope of 0.85 (95% CI = 0.67 to 1.10), and the corresponding performance of the penalised regression model was 0.73 (95% CI = 0.69 to 0.78) and 0.99 (95% CI = 0.72 to 1.19), respectively. \(^2\)The study by Hansen et al was a reference category. The item ‘Lindbaek’ is defined as positive when physicians judge ‘this patient is likely to need antibiotic treatment’. The item ‘Auto’ is generally defined as negative as a setting including only military patients is very likely in clinical practice. ARS = acute rhinosinusitis. AUC = area under the curve. CRP = C-reactive protein. CT = computed tomography. IQR = interquartile range. URTI = upper respiratory tract infection.

Culture-confirmed ABRS. Between-study heterogeneity could not be adequately evaluated for the model for culture-confirmed ABRS, as only two studies were available with Auto et al having only eight events.\(^1\) In the absence of clear statistical support or objections, in the current study a decision was taken to pool the two datasets. The penalised model including three variables showed the best performance with an optimism-corrected AUC of 0.70 (95% CI = 0.63 to 0.77) and a calibration slope of 1.00 (95% CI = 0.66 to 1.52) (Table 3). The three variables were:

- pain in teeth;
- purulent nasal discharge on examination;
- log-transformed CRP.

Fever and severe pain did not have any added value. A web calculator of the penalised model is available online (https://pred-model.shinyapps.io/App_ABRS).

Clinical utility of the derived models

The consequence of using the models at various thresholds is illustrated in Supplementary Table S5. Here, for illustrative purposes, the authors have assumed that the culture-confirmed ABRS model is used and antibiotics are withheld in patients with an estimated outcome risk ≤0.3, while considering antibiotic treatment in those with a risk >0.6 (Figure 2). In this scenario, antibiotics would be withheld in 133/225 patients (59.1%, 95% CI = 52.6 to 65.3) at a cost of misclassification — that is, antibiotics are withheld despite having culture-confirmed ABRS — in 24/133 patients (18.0%, 95% CI = 12.4 to 25.4). On the other hand, antibiotics would be considered in only 9/225 patients (4.0%, 95% CI = 2.1 to 7.4), and 3/9 patients (33.3% 95% CI = 12.1 to 64.6) would be misclassified (that is, antibiotics would be considered despite not having culture-confirmed ABRS). This would leave a substantial group of patients (36.9%, n = 83/225) having an intermediate outcome risk (between 0.3 and 0.6) and still posing a diagnostic challenge. Also, validation in further datasets is required before adoption of these models in daily practice.

DISCUSSION

Summary

In this diagnostic IPD-MA, models were developed with moderate performance for predicting CT-confirmed ARS, defined by a presence of a fluid level or total opacification in any maxillary sinus, and culture-confirmed
Table 3. Regression coefficients of the prediction model for culture-confirmed ABRS

| Coefficient | Standard error | t-value | P-value |
|-------------|----------------|---------|---------|
| Intercept   | 3.21           | 1.04    | <0.01   | -2.89   |
| Previous diagnosis of ARS | -0.29         | 0.35    | 0.41    | 0.00    |
| Preceding URTI | 0.55         | 0.49    | 0.27    | 0.00    |
| Maxillary pain | -0.11         | 0.64    | 0.86    | 0.00    |
| Pain in teeth | 0.85          | 0.36    | 0.22    | 0.73    |
| Anosmia | -0.11          | 0.34    | 0.75    | 0.00    |
| Cacosmia | -0.06          | 0.36    | 0.86    | 0.00    |
| Double sickening | 0.13          | 0.75    | 0.87    | 0.00    |
| Purulent nasal discharge on examination | 0.43          | 0.35    | 0.22    | 0.46    |
| Log-transformed CRP | 0.55          | 0.16    | <0.01   | 0.53    |

The ordinary logistic regression model showed an optimism-corrected AUC of 0.68 (95% CI = 0.62 to 0.75) and a calibration slope of 0.74 (95% CI = 0.47 to 1.06), and the corresponding performance of the penalised regression model was 0.70 (95% CI = 0.63 to 0.77) and 1.00 (95% CI = 0.66 to 1.52), respectively. ABRS = acute bacterial rhinosinusitis. AUC = area under the curve. CRP = C-reactive protein. URTI = upper respiratory tract infection.

ABRS, defined by positive growth of bacterial pathogens in fluid from antral puncture. The CT-confirmed ARS model consisted of seven variables [previous diagnosis of ARS, preceding URTI, anosmia, double sickening, purulent nasal discharge on examination, need for antibiotics as judged by physician, and CRP], whereas the model for culture-confirmed ABRS consisted of only three variables [pain in teeth, purulent nasal discharge on examination, and CRP]. Clinical utility analyses showed that both models could be particularly useful for ruling out the target condition, and thereby withholding antibiotics in a substantial number of patients at a cost of relatively few misclassified patients.

Strengths and limitations

To the authors’ knowledge, this is the first IPD-MA, using state-of-the-art methodology, to develop generalisable prediction models for CT-confirmed ARS and culture-confirmed ABRS, target conditions associated with antibiotic benefit in adults presenting to primary care with suspected ARS.

Still, for full appreciation of the derived models, some limitations deserve attention. First, despite the authors’ efforts in the current study to obtain all available data, data from two studies14,15 were unavailable for inclusion. Thus, the number of available studies and participants was relatively small. Particularly for the culture-confirmed ABRS model, between-study heterogeneity could not be adequately evaluated as there were only two available studies.12,13

Second, although focusing on studies conducted in primary care, the prevalence of the target conditions varied substantially across studies likely owing to differences in eligibility criteria. For the CT-confirmed ARS model, in the current study it was necessary to include a predictor ‘this patient is likely to need antibiotic treatment’ (‘yes’ versus ‘unknown’) to reduce heterogeneity. Individual physician’s subjective judgement of this predictor might affect the stability of the model performance.

Third, because of the limited sample size, the number of candidate predictors for developing the model for culture-confirmed ABRS slightly exceeded the sample size guidance, which increased the risk of overfitting. Finally, CT-confirmed ARS and culture-confirmed ABRS was used as a surrogate for antibiotic benefit. However, the presence of these target conditions does not necessarily imply that antibiotic treatment is required. In a previous trial of adults with CT-confirmed ARS, patients allocated to antibiotics were more likely to report symptom improvement after 10 days than those receiving placebo (86% versus 57%, respectively).11 Albeit this result indicates that antibiotics have beneficial effects among patients with CT-confirmed ARS, it also means that a large number of patients with positive CT findings may recover spontaneously. Similarly, people with culture-confirmed ABRS can spontaneously recover without antibiotic treatment. Given the indirect association between antibiotic benefit and those two target conditions, the derived models are less suitable for ruling in the target conditions and thereby guiding which patients require antibiotics. Conversely, the models can be useful for ruling out the need for antibiotics as it is very unlikely that antibiotics are beneficial in patients without any signs of fluid level or total opacification on CT scan or those with negative bacterial culture of antral fluid.
Comparison with existing literature

Previous prediction models were derived from only one study with insufficient sample size. In addition, predictive information of continuous variables such as CRP was not fully incorporated in previous models.

Implications for research and practice

Despite recommendations in existing practice guidelines to consider antibiotics only for patients with prolonged or severe symptoms, antibiotics are commonly prescribed in patients with ARS. By providing an absolute risk estimate of CT-confirmed ARS and culture-confirmed ABRS the derived models have the potential to guide GPs in high-prescribing countries such as the US and the UK to safely reduce antibiotic prescriptions. Both models have the potential to be implemented in daily practice as they consist of readily available variables. For CT-confirmed ARS these are: 1) previous diagnosis of ARS; 2) preceding URTI; 3) anosmia; 4) double sickening; 5) purulent nasal discharge on examination; 6) need for antibiotics as judged by physician; and 7) CRP. For culture-confirmed ABRS these are: 1) pain in teeth; 2) purulent nasal discharge on examination; and 3) CRP.

For ease of use in clinical practice, the model for culture-confirmed ABRS is simpler than the CT-confirmed ARS model. Furthermore, it does not rely on subjective predictor assessment. However, as the models have been derived from a relatively small IPD set, uncertainty of model estimation and its performance remains. As a result, evaluation of the models’ performance outside the context of this IPD set is still warranted before implementation in everyday practice. In addition, the optimal risk thresholds for ruling out the target condition as a proxy for withholding antibiotic treatment are likely to differ across countries because of variation in medical resource accessibility, clinicians’ prescribing habits, and patient perceptions and demands. Establishing the optimum thresholds in adults with clinically diagnosed ARS, as previously reported for community-acquired pneumonia, has the potential to assist GPs with clinical decision making in their own setting.

In conclusion, in this IPD-MA, prediction models were developed with fair discrimination and calibration for target conditions associated with antibiotic benefit based on readily available variables. Both models have the potential to assist GPs to rule out the target condition and thereby safely reduce antibiotic prescriptions in high-prescribing countries, but this has to be confirmed in future external validation and impact studies.

---

Funding

The Netherlands Organisation for Health Research and Development (grant reference: 91618026).

Ethical Approval

There are no identifiable patient data in any of the datasets. As such, the Medical Research Involving Humans Subject Act (WMO) does not apply to this study. The Medical Ethics Review Committee Utrecht, the Netherlands, reviewed the study protocol (protocol: 20-331/C) and concluded that an official approval was not required.

Data

Data will be available to researchers who provide a methodologically sound proposal to achieve the aims in the approved proposal. Proposals should be directed to the corresponding author to gain access to the data. Data requesters will need to sign a data-sharing agreement.

Provenance

Freely submitted; externally peer reviewed.

Competing interests

The authors have declared no competing interests.

Open access

This article is Open Access: CC BY 4.0 licence (http://creativecommons.org/licenses/by/4.0/).

Discuss this article

Contribute and read comments about this article: bjgp.org/letters
